After more than three years of effort and a couple of reinspections, India’s Sun Pharma has been unable to satisfy the FDA's expectations for its key plant.Original Article
Sun says FDA again faults plant that is its key launch site for U.S. drugs
You may also like
New alloys for manufacturing freeze-dryers
Navigating the Complexities of Emerging Therapy...
INTERPHEX 2025: Preventing Spills in the Manufacturing...
Agentic AI Growth Predicted, but More Than Half of...
Microsoft and SkyCell Collaborate on Pharma Supply...
Siemens Acquires Dotmatics, Extending AI Software...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.